Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Weiguo Ye | $196,951 | $0 | $0 | $4,460,335 | $344,398 | $0 | $22,065 | $5,023,749 |
| Chief Operating Officer | ||||||||
| Ping Zhang | 189,777 | 0 | 0 | 3,795,596 | 100,000 | 0 | 11,250 | 4,096,623 |
| Interim Chief Executive Officer | ||||||||
| Han Ying | 309,018 | 0 | 0 | 0 | 35,000 | 0 | 9,297 | 353,315 |
| Senior Vice President, Science and Former Chief Executive Officer | ||||||||
| Ruoyu Chen | 250,000 | 0 | 0 | 0 | 25,000 | 0 | 10,583 | 285,583 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Weiguo Ye | $5,023,749 | — | — | — |
| Ping Zhang | 4,096,623 | — | — | — |
| Han Ying | 353,315 | — | — | — |
| Ruoyu Chen | 285,583 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ping Zhang | Option | 250,000 | 6.92 | — |
| Ping Zhang | Option | 250,000 | 10.18 | — |
| Ping Zhang | Option | 36,111 | 10.79 | — |
| Ruoyu Chen | Option | 33,333 | 9.98 | — |
| Weiguo Ye | Option | 243,750 | 10.32 | — |
| Han Ying | Option | 227,333 | 9.98 | — |
| Han Ying | Option | 622 | 6.93 | — |
Compensation is designed to attract and retain executive talent, consisting of base salary, performance-based bonus, standard benefits, and equity incentives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon/Radford |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 70,478,374 | 34,907 | 1,160 | 99.95% | Passed |
| 2025 | 2025-06-04 | 69,505,961 | 39,318 | 1,936 | 99.94% | Passed |
| 2024 | 2024-06-12 | 69,101,285 | 7,487 | 3,218 | 99.99% | Passed |
| 2022 | 2022-08-15 | 13,562,097 | 3,818,837 | 95,674 | 78.03% | Passed |
| 2021 | 2021-06-09 | 15,954,188 | 2,118,540 | 36,039 | 88.28% | Passed |
| 2020 | 2020-06-11 | 7,558,191 | 817,272 | 739,153 | 90.24% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | 99.95%a |
| 2025 | 2025-06-04 | 99.94%b |
| 2024 | 2024-06-12 | 99.99%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 9,000 / 14,000 / 10,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Gyre Therapeutics | 2025 | Ping Zhang | $189,777 | $0 | $3,795,596 | $100,000 | $4,096,623 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Weiguo Ye | DEF 14A | 2026-04-27 | 0001140361-26-017124 | Section “Executive Compensation”. As printed: 5,023,749. Filing ↗machine: r5 · c21 · span 355073–355082 |
| 2 | Section 01, Ping Zhang | DEF 14A | 2026-04-27 | 0001140361-26-017124 | Section “Executive Compensation”. As printed: 4,096,623. Filing ↗machine: r2 · c21 · span 343050–343059 |
| 3 | Section 01, Han Ying | DEF 14A | 2026-04-27 | 0001140361-26-017124 | Section “Executive Compensation”. As printed: 353,315. Filing ↗machine: r7 · c21 · span 363070–363077 |
| 4 | Section 01, Ruoyu Chen | DEF 14A | 2026-04-27 | 0001140361-26-017124 | Section “Executive Compensation”. As printed: 285,583. Filing ↗machine: r3 · c21 · span 347153–347160 |
| 5 | Section 06, 2026 vote | Form 8-K | 2026-06-16 | 0001140361-26-025324 | Item 5.07 · say-on-pay result. As reported: 99.95% (votes for as printed: 70,478,374). Filing ↗ |
| 6 | Section 06, 2025 vote | Form 8-K | 2025-06-06 | 0001140361-25-021612 | Item 5.07 · say-on-pay result. As reported: 99.94% (votes for as printed: 69,505,961). Filing ↗ |
| 7 | Section 06, 2024 vote | Form 8-K | 2024-06-17 | 0001140361-24-030348 | Item 5.07 · say-on-pay result. As reported: 99.99% (votes for as printed: 69,101,285). Filing ↗ |
| 8 | Gyre Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017124 | CEO total compensation as printed in Gyre Therapeutics's own proxy. As printed: 4,096,623. Filing ↗machine: r2 · c21 · span 343050–343059 |